Could a malaria drug help fight resistant colon cancer?
NCT ID NCT05576896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding hydroxychloroquine (a drug used for malaria) to standard targeted therapy can help shrink tumors in people with advanced colorectal cancer that has a specific BRAF mutation and has stopped responding to prior treatments. The trial enrolled 7 adults with stage IV disease. The goal is to see if blocking a process called autophagy can overcome treatment resistance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States